Cargando…
International Undiagnosed Diseases Programs (UDPs): components and outcomes
Over the last 15 years, Undiagnosed Diseases Programs have emerged to address the significant number of individuals with suspected but undiagnosed rare genetic diseases, integrating research and clinical care to optimize diagnostic outcomes. This narrative review summarizes the published literature...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633944/ https://www.ncbi.nlm.nih.gov/pubmed/37946247 http://dx.doi.org/10.1186/s13023-023-02966-1 |
_version_ | 1785132721740185600 |
---|---|
author | Curic, Ela Ewans, Lisa Pysar, Ryan Taylan, Fulya Botto, Lorenzo D. Nordgren, Ann Gahl, William Palmer, Elizabeth Emma |
author_facet | Curic, Ela Ewans, Lisa Pysar, Ryan Taylan, Fulya Botto, Lorenzo D. Nordgren, Ann Gahl, William Palmer, Elizabeth Emma |
author_sort | Curic, Ela |
collection | PubMed |
description | Over the last 15 years, Undiagnosed Diseases Programs have emerged to address the significant number of individuals with suspected but undiagnosed rare genetic diseases, integrating research and clinical care to optimize diagnostic outcomes. This narrative review summarizes the published literature surrounding Undiagnosed Diseases Programs worldwide, including thirteen studies that evaluate outcomes and two commentary papers. Commonalities in the diagnostic and research process of Undiagnosed Diseases Programs are explored through an appraisal of available literature. This exploration allowed for an assessment of the strengths and limitations of each of the six common steps, namely enrollment, comprehensive clinical phenotyping, research diagnostics, data sharing and matchmaking, results, and follow-up. Current literature highlights the potential utility of Undiagnosed Diseases Programs in research diagnostics. Since participants have often had extensive previous genetic studies, research pipelines allow for diagnostic approaches beyond exome or whole genome sequencing, through reanalysis using research-grade bioinformatics tools and multi-omics technologies. The overall diagnostic yield is presented by study, since different selection criteria at enrollment and reporting processes make comparisons challenging and not particularly informative. Nonetheless, diagnostic yield in an undiagnosed cohort reflects the potential of an Undiagnosed Diseases Program. Further comparisons and exploration of the outcomes of Undiagnosed Diseases Programs worldwide will allow for the development and improvement of the diagnostic and research process and in turn improve the value and utility of an Undiagnosed Diseases Program. |
format | Online Article Text |
id | pubmed-10633944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106339442023-11-10 International Undiagnosed Diseases Programs (UDPs): components and outcomes Curic, Ela Ewans, Lisa Pysar, Ryan Taylan, Fulya Botto, Lorenzo D. Nordgren, Ann Gahl, William Palmer, Elizabeth Emma Orphanet J Rare Dis Review Over the last 15 years, Undiagnosed Diseases Programs have emerged to address the significant number of individuals with suspected but undiagnosed rare genetic diseases, integrating research and clinical care to optimize diagnostic outcomes. This narrative review summarizes the published literature surrounding Undiagnosed Diseases Programs worldwide, including thirteen studies that evaluate outcomes and two commentary papers. Commonalities in the diagnostic and research process of Undiagnosed Diseases Programs are explored through an appraisal of available literature. This exploration allowed for an assessment of the strengths and limitations of each of the six common steps, namely enrollment, comprehensive clinical phenotyping, research diagnostics, data sharing and matchmaking, results, and follow-up. Current literature highlights the potential utility of Undiagnosed Diseases Programs in research diagnostics. Since participants have often had extensive previous genetic studies, research pipelines allow for diagnostic approaches beyond exome or whole genome sequencing, through reanalysis using research-grade bioinformatics tools and multi-omics technologies. The overall diagnostic yield is presented by study, since different selection criteria at enrollment and reporting processes make comparisons challenging and not particularly informative. Nonetheless, diagnostic yield in an undiagnosed cohort reflects the potential of an Undiagnosed Diseases Program. Further comparisons and exploration of the outcomes of Undiagnosed Diseases Programs worldwide will allow for the development and improvement of the diagnostic and research process and in turn improve the value and utility of an Undiagnosed Diseases Program. BioMed Central 2023-11-09 /pmc/articles/PMC10633944/ /pubmed/37946247 http://dx.doi.org/10.1186/s13023-023-02966-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Curic, Ela Ewans, Lisa Pysar, Ryan Taylan, Fulya Botto, Lorenzo D. Nordgren, Ann Gahl, William Palmer, Elizabeth Emma International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title | International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title_full | International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title_fullStr | International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title_full_unstemmed | International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title_short | International Undiagnosed Diseases Programs (UDPs): components and outcomes |
title_sort | international undiagnosed diseases programs (udps): components and outcomes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633944/ https://www.ncbi.nlm.nih.gov/pubmed/37946247 http://dx.doi.org/10.1186/s13023-023-02966-1 |
work_keys_str_mv | AT curicela internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT ewanslisa internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT pysarryan internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT taylanfulya internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT bottolorenzod internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT nordgrenann internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT gahlwilliam internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes AT palmerelizabethemma internationalundiagnoseddiseasesprogramsudpscomponentsandoutcomes |